Kitchen L W, Mather F J, Chapple F E, Bilello J A
Section of Infectious Diseases, Marshall University School of Medicine, Huntington, WV 25703.
J Clin Lab Immunol. 1990 Nov;33(3):97-105.
Previous studies indicate that decreased serum viral infectivity and viral antigen levels follow oral administration of diethylcarbamazine (DEC) in feline leukemia virus infected cats, even though DEC has not been shown to exhibit in vitro antiviral activity. In this investigation, DEC was given by oral administration or (single dose) IP injection to murine leukemia virus (Cas-Br-M) inoculated mice to permit evaluation of its effect on viral-induced central nervous system disease. The survival of Cas-Br-M inoculated mice receiving DEC in water was significantly prolonged relative to similarly inoculated mice receiving distilled water. Among the Cas-Br-M inoculated mice euthanatized after the study, higher body weights and trend toward less severe brain and splenic lesions were noted in those receiving DEC in drinking water. Given these results, the possible utility of DEC in treatment of retroviral and other infections warrants further study.
先前的研究表明,在感染猫白血病病毒的猫中口服乙胺嗪(DEC)后,血清病毒感染性和病毒抗原水平会降低,尽管尚未证明DEC在体外具有抗病毒活性。在本研究中,对接种了鼠白血病病毒(Cas-Br-M)的小鼠口服或腹腔注射(单剂量)DEC,以评估其对病毒诱导的中枢神经系统疾病的影响。相对于接受蒸馏水的类似接种小鼠,在水中接受DEC的接种Cas-Br-M的小鼠的存活时间显著延长。在研究结束后实施安乐死的接种Cas-Br-M的小鼠中,饮用水中添加DEC的小鼠体重更高,且脑和脾脏病变的严重程度有减轻的趋势。鉴于这些结果,DEC在治疗逆转录病毒感染和其他感染方面的潜在效用值得进一步研究。